LEVERAGING KNOWLEDGE - DRIVING PERFORMANCE - DESIGNING THE FUTURE

Clinical Forum Teams work extensively with industry, healthcare organisations, academia regulators to link stakeholders and to facilitate the development of the environment for electronic clinical research. We have conducted surveys, developed tools, built an extensive base of knowledge of information relevant to the successful implementation of eClinical solutions.

Join the eClinical Forum to participate in cross-industry initiatives and to benefit from early access to pre-competitive information on best practices and trends.

ECF Teams and Projects

2003: eCF Presentation to EMEA GCP Inspectors on EDC 22 October 20030

2003: eCF Presentation to EMEA GCP Inspectors on EDC

Please download to review this presentation.

THE USE OF ELECTRONIC SOURCE DOCUMENTATION - V1.1 May 2003 12 May 20030

THE USE OF ELECTRONIC SOURCE DOCUMENTATION - V1.1 May 2003

This 13-page position paper on eSource (source data that has been captured by an electronic tool which is a replacement for paper) describes the regulatory environment for the ultimate benefit of all stakeholders involved in EDC.

2003: Regulatory Environment for Electronic Data Capture 12 February 20030

2003: Regulatory Environment for Electronic Data Capture

Please download to review this report.

2001: Cost / Benefit Analysis of EDC 12 December 20010

2001: Cost / Benefit Analysis of EDC

Please download to review this report.

2001: Investigator Survey 12 June 20010

2001: Investigator Survey

The eClinical Forum has conducted a global survey of investigational site experiences and expectations with EDC. The survey covers:

* Computer use and site facilities.
* Current experience with EDC.
* Satisfaction with EDC features.
* Future expectations.

1999: Industry Survey 03 January 20000

1999: Industry Survey

A survey was undertaken by the eClinical Forum to review the pharmaceutical industry’s experience to date with Electronic Data Capture (EDC) and to better understand future trends.

The survey report incorporates the responses of 30 companies, and includes a mixture of EU and US ethical pharmaceutical and biotechnology companies representing 8 of the top 10, 12 of the top 20 and 18 of the top 40 by revenue.

12345